[
  {
    "ts": null,
    "headline": "Regeneron (REGN): Revisiting Valuation After Recent Pullback and 90-Day Share Price Surge",
    "summary": "Regeneron Pharmaceuticals (REGN) shares have drifted lower over the past week even as the stock remains solidly higher over the past 3 months, setting up an interesting check on valuation and expectations. See our latest analysis for Regeneron Pharmaceuticals. That recent 7 day share price pullback sits against a strong 90 day share price return of 21.89% and a more muted 1 year total shareholder return of minus 9.91%. This suggests shorter term momentum is improving even as longer term gains...",
    "url": "https://finnhub.io/api/news?id=12e7cabb78f050b6ca74dfca6144271631b76776394deeb3308bafa417824ee4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765375812,
      "headline": "Regeneron (REGN): Revisiting Valuation After Recent Pullback and 90-Day Share Price Surge",
      "id": 137750522,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (REGN) shares have drifted lower over the past week even as the stock remains solidly higher over the past 3 months, setting up an interesting check on valuation and expectations. See our latest analysis for Regeneron Pharmaceuticals. That recent 7 day share price pullback sits against a strong 90 day share price return of 21.89% and a more muted 1 year total shareholder return of minus 9.91%. This suggests shorter term momentum is improving even as longer term gains...",
      "url": "https://finnhub.io/api/news?id=12e7cabb78f050b6ca74dfca6144271631b76776394deeb3308bafa417824ee4"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript",
    "summary": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma December 10, 2025 8:30 AM...",
    "url": "https://finnhub.io/api/news?id=6074607a3578b2d37ff1253a1bf8b3f7b046fcb9ba3b89123d117c49525aee20",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765370571,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript",
      "id": 137748645,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma December 10, 2025 8:30 AM...",
      "url": "https://finnhub.io/api/news?id=6074607a3578b2d37ff1253a1bf8b3f7b046fcb9ba3b89123d117c49525aee20"
    }
  }
]